HER-2 profiling and targeting in prostate carcinoma: A phase II trial of trastuzumab alone and with paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Combined Chemotherapy Protocols
Gene Expression Regulation, Neoplastic
Trastuzumab is not effective as a single agent for the treatment of patients with AI HER-2 negative tumors. HER-2 expression varies by clinical state in patients with prostate carcinoma: Accurate HER-2 profiling requires sampling metastatic tissue in patients with metastatic disease. Further development of trastuzumab for the treatment of patients with metastatic prostate carcinoma is not feasible until more reliable and practical methods of sampling metastatic disease are developed to identify patients with HER-2 positive tumors.